论文部分内容阅读
血管紧张素转化酶抑制剂被认为是用于治疗慢性充血性心力衰竭(简称心衰)的一类新型血管扩张剂。国内临床报道尚少,我院近年采用该药治疗难治性心衰患者23例,疗效为显著,现报告如下。 1 临床资料和方法 1.1 临床资料:男13例,女10例,均为住院患者。年龄20～87岁,风心病12例,冠心病3例,高血压心脏病5例,扩张型心肌病1例,限制型心肌病(经剖胸探查证实)1例,肺心病1例,心衰时间2个月至30年;心功能按N—VHA分级,Ⅳ15例,Ⅲ级8例。 1.2 诊断标准:上述病例临床均有慢性心衰的症状和体征,且入院前应用常规治疗(休息、抗感染、利尿及洋地黄等)未能改善心衰状态。23例患者入院后均经心电
Angiotensin converting enzyme inhibitors are considered as a new class of vasodilators for the treatment of chronic congestive heart failure (HF). Domestic clinical reports are still less, our hospital in recent years with the drug treatment of refractory heart failure in 23 patients, the effect was significant, are as follows. 1 Clinical data and methods 1.1 Clinical data: 13 males and 10 females, all hospitalized patients. Aged 20-87 years, 12 cases of rheumatic heart disease, 3 cases of coronary heart disease, 5 cases of hypertensive heart disease, 1 case of dilated cardiomyopathy, 1 case of restricted cardiomyopathy confirmed by thoracotomy, 1 case of pulmonary heart disease, Decline for two months to 30 years; cardiac function by N-VHA classification, Ⅳ Ⅳ cases, Ⅲ grade in 8 cases. 1.2 diagnostic criteria: The clinical symptoms and signs of clinical symptoms of chronic heart failure, and the application of conventional treatment before admission (rest, anti-infective, diuretic and digitalis, etc.) failed to improve the state of heart failure. Twenty-three patients had ECG after admission